河北医科大学学报

• 论著 • 上一篇    下一篇

心脑血管疾病与同型半胱氨酸临床干预关系的Meta分析

  

  1. 1.河北医科大学公共卫生学院2013级卫生检验与检疫学专业,河北 石家庄 050017;2.河北医科大学公共卫生学院
    流行病与卫生统计学教研室,河北 石家庄 050017;3.河北医科大学第二医院神经外科, 河北 石家庄 050000
  • 出版日期:2017-11-25 发布日期:2017-11-16
  • 作者简介:马芳芳(1993-),女,河北邯郸人,河北医科大学公共卫生学院卫生检验与检疫学专业本科生,从事卫生检验与检疫学研究。
  • 基金资助:
    河北医科大学“大学生创新性实验计划”项目(USIP2016174);河北省医学科学研究重点课题(1120140146)

The relationship between cardiovascular and cerebrovascular diseases and the clinical intervention of homocysteine:a Metaanalysis#br#

  1. 1.2013 Grade Health Inspection and Quarantine Specialty, School of Public Health, Hebei Medical University,
    Shijiazhuang 050017, China; 2.Department of Epidemiology and Statistics, School of Public Health,
    Hebei Medical University, Shijiazhuang 050017, China; 3.Department of Neurosurgery, the
    Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
  • Online:2017-11-25 Published:2017-11-16

摘要: [摘要]〓
〖HTH〗目的〖HTSS〗〖KG*2〗评价临床干预降低心脑血管疾病患者或伴高血浆同型半胱氨酸(homocysteine,HCY)人群的HCY水平对预防心脑血管疾病的作用。
〖HTH〗方法〖HTSS〗〖KG*2〗 以“心脑血管疾病”、“同型半胱氨酸”、“干预”、“cardiovascular disease”、“homocysteine” 、“HCY”等为检索词,检索CNKI、CBM、Pubmed、OVID等数据库,采用RevMan 5.3软件进行Meta分析。
〖HTH〗结果〖HTSS〗〖KG*2〗共纳入15篇随机对照试验(共45 611例)。试验组与对照组之间心脑血管疾病发生、卒中再发差异均有统计学意义。各亚组心脑血管疾病(0<x≤24、24<x≤48和48<x≤72个月)的OR值(95%CI)分别为0.390(0.260~0.600)、0.980(0.840~1.160)、0.840(0.730~0.970);各亚组卒中再发的OR值(95%CI)分别为0.780(0.620~0.990)、0.320(0.210~0.480)。
〖HTH〗结论〖HTSS〗〖KG*2〗干预HCY时合理控制干预时间(即选择0<x≤24、48<x≤72个月可以达到防治心脑血管疾病的目的;应用叶酸、维生素B12、维生素B6干预均有防治卒中的作用。故推荐将干预HCY作为心脑血管疾病的二级预防措施。

关键词: 心血管疾病, 脑血管疾病, Meta分析

Abstract: [Abstract] Objective〖HTSS〗〓To evaluate the effect of clinical intervention on reducing homocysteine (HCY) levels in patients with cardiovascular and cerebrovascular diseases or with high HCY, and to prevent cardiovascular and cerebrovascular diseases.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓CNKI, CBM, Pubmed, OVID and other databases were retrieved by “heart and cerebrovascular disease”, “homocysteine”, “HCY”, “intervention”, “cardiovascular disease” and “homocysteine”. RevMan 5.3 software was used for Metaanalysis.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓A total of 15 randomized controlled trials(45 611 patients) were included. According to the results of Metaanalysis, the difference of cardiovascular and cerebrovascular disease or stroke between the experimental and the control group was statistically significant. For the occurrence of cardiovascular and cerebrovascular disease (0<x≤24, 24<x≤48 and 48<x≤72 months),the pooled OR(95% CI) were 0.390(0.260-0.600), 0.980(0.840-1.160), 0.840(0.730-0.970) in subgroups. For the relapse of stroke, the pooled OR(95% CI) were 0.780(0.620-0.990), 0.320(0.210-0.480) in subgroups were divided according to the treatment plan.
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓It has a protective effect on cardiovascular disease if control the intervention time(0<x≤24 and 48<x≤72 months) when interfering with the level of HCY. Folic acid, Vitamin B12 and Vitamin B6 have preventive and therapeutic effects on the occurrence and relapse of stroke. It is suggested that the intervention HCY as secondary prevention measures for cardiovascular and cerebrovascular diseases.

Key words: cardiovascular diseases, cerebrovascular disease, Metaanalysis